| 영문 | protein | 한글 | 단백질 |
|---|---|---|---|
| 설명 | 탄소, 수소, 산소, 질소, 황을 함유하고 있는 유기화합물로, 모든 세포의 원형질을 이루고 있는 기본 구성물질이다. 단백질은 그 단위인 아미노산들이 펩티드결합에 의해 결합되어 있으며, 보통 20개의 아미노산들이 다른 순서와 조성을 가지고 배열되어, 독특한 하나의 단백질을 형성하게 된다. |
||
| MAP | malignant atrophic papulosis; mandibular angle plane; maturation-activated protein; maximal aerobic ... |
|---|---|
| MBP | major basic protein; maltose-binding protein; management by policy; mannose-binding protein; mean bl... |
| RP | radial pulse; radiopharmaceutical; rapid processing [of film]; Raynaud phenomenon; reactive protein;... |
| HMO | Health Maintenance Organization; 건강 유지 조직 |
| BCMS | Bioethic Citation Maintenance System |
| HMO | Health Maintenance Organization |
|---|---|
| M | P)-maintenance |
| MHD | Maintenance hemodialysis |
| MWT | Maintenance of Wakefulness Test |
| MM | Methadone Maintenance |
| air quality maintenance area | Specific populated area where air quality is a problem for one or more pollutants (Portland-Vancouver, Salem, Eugene-Springfield, Medford-Ashland). (05 Dec 1998) |
|---|---|
| maintenance | The upkeep of property or equipment. (12 Dec 1998) |
| maintenance and engineering, hospital | Hospital department whose primary function is the upkeep and supervision of the buildings and grounds and the maintenance of hospital physical plant and equipment which requires engineering expertise. (12 Dec 1998) |
| maintenance dose | In chemotherapy, systematic dosage at a level that maintains protection against exacerbation. (05 Mar 2000) |
| maintenance drug therapy | In chemotherapy, systematic dosage at a level that maintains protection against exacerbation. (05 Mar 2000) |
| maintenance medication | Medication taken to stabilise an illness or symptoms of illness. (05 Mar 2000) |
| maintenance therapy | Extended drug therapy, usually at a diminished dose, administered after a disease has been brought under control. Maintenance therapy is utilised when a complete cure is not possible, and a disease is likely to recur if therapy is halted. (09 Oct 1997) |
| maintenance treatment | Treatment given for a period of months or years to maintain remission and eliminate any residual leukaemic cells in the body, usually for acute lymphoblastic leukaemia. (13 Nov 1997) |
| corpus luteum maintenance | Physiologic and biochemical factors that maintain an actively functioning corpus luteum. (12 Dec 1998) |
| pregnancy maintenance | Physiological mechanisms that sustain the state of pregnancy. (12 Dec 1998) |
| health maintenance organization | A comprehensive prepaid system of health care with emphasis on the prevention and early detection of disease, and continuity of care.HMOs may be nonprofit or profit-making ventures, and along with PPOs and managed care plans have come to define the U.S. Health care scene. HMOs generally offer a package of services; however, the choice of physician is frequently limited to those working within the HMO. (05 Mar 2000) |
| health maintenance organizations | Organised systems for providing comprehensive prepaid health care that have five basic attributes: 1) provide care in a defined geographic area; 2) provide or ensure delivery of an agreed-upon set of basic and supplemental health maintenance and treatment services; 3) provide care to a voluntarily enrolled group of persons; 4) require their enrollees to use the services of designated providers; and 5) receive reimbursement through a predetermined, fixed, periodic prepayment made by the enrollee without regard to the degree of services provided. (12 Dec 1998) |
| acetoacetyl-acyl carrier protein synthase | <enzyme> E coli enzyme, that catalyses condensation of malonyl-acyl carrier protein plus acetyl-acyl carrier protein; not inhibited by cerulenin Registry number: EC 2.3.1.- Synonym: acetoacetyl-acp synthase (26 Jun 1999) |
| acid soluble spore protein | <molecular biology> A DNA binding protein in the spores of some bacteria, thought to stabilise the DNA in an A configuration, so protecting it from cleavage by enzymes or UV light. (18 Nov 1997) |
| acute-phase protein | <haematology> These plasma proteins (in addition to fibrinogen) increase 25% or more in response to inflammation and injury are under direct control of interleukin-6 (IL-6) (hepatocyte-stimulating factor). Other proteins which increase are ceruloplasmin, C3 and C4 which increase 50% or more; alpha-1 acid glycoprotein, alpha-1 antitrypsin, haptoglobin and fibrinogen (the major determinant of viscosity 1 ) which increase two- to fourfold; C-reactive protein (CRP) and serum amyloid A which increase several hundred-fold. Despite long-held clinical opinion to the contrary, available data indicate that neither ESR nor measurement of specific acute-phase reactants are useful in excluding underlying infection or inflammation regardless of the pretest probability. These proteins are secreted into the blood in increased or decreased quantities by hepatocytes in response to trauma, inflammation, or disease. They can serve as inhibitors or mediators of the inflammatory processes. Certain acute-phase proteins have been used to diagnose and follow the course of diseases or as tumour markers. See also: amyloid, c-reactive protein, erythrocyte sedimentation rate, viscosity. (25 Jun 1999) |
| maintenance protein |
the smallest amount of protein upon which the normal conditions of the body can be maintained.
출처: www.mercksource.com/pp/us/cns/cns_hl_dorlands.jspz...
|
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|